Added to YB: 2025-03-14
Pitch date: 2025-01-24
LYEL [bullish]
Lyell Immunopharma, Inc.
+47.26%
current return
Author Info
No bio for this author
Company Info
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
Market Cap
$451.0M
Pitch Price
$11.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.37
P/E
-1.48
EV/Sales
7.4K
Sector
Biotechnology
Category
growth
Lyell Immunopharma, Inc. - $LYEL
LYEL: Trading at 40% of Q4 cash post ImmPACT merger. IMPT-314 CD19xCD20 CAR-T shows 94% ORR, 71% CR in NHL. Pivotal trial in 2025. $170M cap vs $400M cash. Best-in-class data in $3B+ market. Risks: durability, larger trials. Catalysts: data updates, trial initiations, investor awareness.
Read full article (7 min)